Trial · NCT02442765
Participant flow48
How many started, completed or left each group, period by period.
1 to 20 of 48
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Stage 1- (Days 1 to 42) | STARTED | Stage 1: Placebo | 194 | |
| Stage 1- (Days 1 to 42) | STARTED | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | 96 | |
| Stage 1- (Days 1 to 42) | STARTED | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) | 97 | |
| Stage 1- (Days 1 to 42) | STARTED | Stage 2: Placebo | 0 | |
| Stage 1- (Days 1 to 42) | STARTED | Stage 1: Placebo to: Stage 2: AVP-786-28 d6-DM 18 mg/Q 4.9 mg | 0 | |
| Stage 1- (Days 1 to 42) | STARTED | Stage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mg | 0 | |
| Stage 1- (Days 1 to 42) | STARTED | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | 0 | |
| Stage 1- (Days 1 to 42) | STARTED | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) | 0 | |
| Stage 1- (Days 1 to 42) | COMPLETED | Stage 1: Placebo | 194 | |
| Stage 1- (Days 1 to 42) | COMPLETED | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | 96 | |
| Stage 1- (Days 1 to 42) | COMPLETED | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) | 97 | |
| Stage 1- (Days 1 to 42) | COMPLETED | Stage 2: Placebo | 0 | |
| Stage 1- (Days 1 to 42) | COMPLETED | Stage 1: Placebo to: Stage 2: AVP-786-28 d6-DM 18 mg/Q 4.9 mg | 0 | |
| Stage 1- (Days 1 to 42) | COMPLETED | Stage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mg | 0 | |
| Stage 1- (Days 1 to 42) | COMPLETED | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | 0 | |
| Stage 1- (Days 1 to 42) | COMPLETED | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) | 0 | |
| Stage 1- (Days 1 to 42) | NOT COMPLETED | Stage 1: Placebo | 0 | |
| Stage 1- (Days 1 to 42) | NOT COMPLETED | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | 0 | |
| Stage 1- (Days 1 to 42) | NOT COMPLETED | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) | 0 | |
| Stage 1- (Days 1 to 42) | NOT COMPLETED | Stage 2: Placebo | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02442765/flow